| Videos | Channels | Search |
Berger: Biogen's healthy recovery
Serge Berger suggests buying Biogen, a biotech firm which has reported sales of its Multiple Sclerosis treatment Tecfidera more than tripling.
The Biotech sector suffered a twenty five percent drop in performance earlier this year but results for firms like Biogen show a healthy recovery.
Media coverage has given the stock momentum and Biogen has revised its growth forecast upwards to 38% - 41%.
Wednesday's rally took stock past a multi-week resistance area into a breakaway gap.
Trading also saw a big surge in volume.
Buy: 337.00 USD
Target 360.00 USD
Stop: 322.00 USD
02:06 minutes
Tags: bio tech, bio technology, biogen, biotech, drugs, drugs sector, growth, growth forecast, health, health care, health industry, health stocks, healthcare, healthcare device, healthcare stocks, healthy, multiple, pharma, pharmaceutical, pharmaceutical sales, pharmaceuticals, pharmacies, saxo bank, saxo tv, shares, shares 2014, shares down, shares prices, shares up, shsres, stock, stock correction, stock dividends, stock exchange, stock futures, stock market, stock markets, stock pick, stock picks, stock price, stock prices, stock sales, stock trading, stock trading 2014, stocks, stocks markets, stocks to watch, stocks unstoppable, tradingfloor.com, volume, volumes
Switch to